Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

Baker Capital Strategies

Free Registration

Register for access to news, tools, alerts and reports.

THEMA Basic included at launch.

Use at least 8 characters.

Home/The Filing Wire/TransCode Therapeutics, Inc./ S-1

Registration Statement · S-1

TransCode Therapeutics, Inc.

RNAZNASDAQEQUITYCurrent

Registration Statement

Filed May 1, 2026Accepted Apr 30, 2026, 8:58 PM EDTCIK 1829635Accession 0001104659-26-053289
View company →Permanent SEC source ↗
Share

Company context

TransCode is a clinical-stage company pioneering immuno-oncology and RNA therapeutics for treatment of high risk and advanced cancers We possess a diversified pipeline of therapeutic candidates, including two clinical stage assets, TTX-MC138, an antisense inhibitor of an oncogenic microRNA and Seviprotimut-L, a cancer vaccine. We also possess an oncolytic immunotherapy platform and three TTX-based pre-clinical stage assets.

Current securities

RNAZNASDAQ · EQUITY · Current

Recent company filings

  1. 3 filingSep 21, 2026
  2. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory ArrangementsSep 11, 2026
  3. 10-Q filingAug 14, 2026
  4. Material Modification to Rights of Security Holders · Amendments to Articles of Incorporation or Bylaws; Change in Fiscal YearAug 3, 2026
  5. SCHEDULE 13G filingJul 28, 2026

As-filed source

Primary evidence
As filedOpen full document ↗